- Home
- MCRB vs BCV Comparison
MCRB vs BCV Comparison
Compare MCRB & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- BCV
- Stock Information
- Founded
- MCRB 2010
- BCV 1971
- Country
- MCRB United States
- BCV United States
- Employees
- MCRB N/A
- BCV N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- BCV Finance/Investors Services
- Sector
- MCRB Health Care
- BCV Finance
- Exchange
- MCRB Nasdaq
- BCV Nasdaq
- Market Cap
- MCRB 125.7M
- BCV 115.1M
- IPO Year
- MCRB 2015
- BCV N/A
- Fundamental
- Price
- MCRB $19.44
- BCV $20.37
- Analyst Decision
- MCRB Hold
- BCV
- Analyst Count
- MCRB 4
- BCV 0
- Target Price
- MCRB $73.67
- BCV N/A
- AVG Volume (30 Days)
- MCRB 126.4K
- BCV 26.3K
- Earning Date
- MCRB 08-06-2025
- BCV 01-01-0001
- Dividend Yield
- MCRB N/A
- BCV 8.13%
- EPS Growth
- MCRB N/A
- BCV N/A
- EPS
- MCRB 10.22
- BCV N/A
- Revenue
- MCRB N/A
- BCV N/A
- Revenue This Year
- MCRB N/A
- BCV N/A
- Revenue Next Year
- MCRB N/A
- BCV N/A
- P/E Ratio
- MCRB $1.98
- BCV N/A
- Revenue Growth
- MCRB N/A
- BCV N/A
- 52 Week Low
- MCRB $6.53
- BCV $14.09
- 52 Week High
- MCRB $26.40
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- MCRB 69.44
- BCV 69.70
- Support Level
- MCRB $15.79
- BCV $19.94
- Resistance Level
- MCRB $18.12
- BCV $20.34
- Average True Range (ATR)
- MCRB 1.51
- BCV 0.22
- MACD
- MCRB 0.28
- BCV -0.00
- Stochastic Oscillator
- MCRB 97.69
- BCV 90.82
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.